RESUMEN
Patients with systemic inflammatory and/or autoimmune diseases have an increased risk of infections particularly severe influenza infections. Annually vaccination can prevent these infections. Available data about the influenza vaccine in these patients show that, it remains well tolerated and effective even if the antibody response is lower compared to healthy controls. These data encourage to vaccine every year patients with systemic inflammatory and/or autoimmune diseases with influenza vaccine, particularly patients taking immunosuppressant drugs or having respiratory, cardiac or renal chronic diseases according to guidelines. More data are needed about the severity of influenza infection and the efficacy of influenza vaccination in patients with systemic inflammatory and/or autoimmune diseases to improve their vaccine coverage.
Asunto(s)
Enfermedades Autoinmunes/inmunología , Inflamación/inmunología , Subtipo H1N1 del Virus de la Influenza A/inmunología , Vacunas contra la Influenza/administración & dosificación , Vacunas contra la Influenza/inmunología , Gripe Humana/inmunología , Gripe Humana/prevención & control , Pandemias , Anticuerpos Antivirales/inmunología , Enfermedades Autoinmunes/tratamiento farmacológico , Hemaglutinación por Virus/inmunología , Humanos , Inmunocompetencia/efectos de los fármacos , Inmunocompetencia/inmunología , Inmunosupresores/efectos adversos , Inmunosupresores/uso terapéutico , Inflamación/tratamiento farmacológico , Vacunas contra la Influenza/efectos adversos , Factores de Riesgo , Resultado del TratamientoRESUMEN
Patients with systemic autoimmune and/or inflammatory diseases have an increased risk of infections, particularly pneumoccocal invasive infections. Vaccination can prevent these infections. Available data about immunogenicity and safety of pneumococcal polysaccharide vaccine in these patients indicate that, it remains well tolerated and most of the time immunogenic, even if the antibody response is lower compared to healthy controls. These data encourage to vaccinate these patients with pneumococcal vaccine. However, the lack of data confirming the clinical efficacy of this vaccination, the theoretical risk of disease relapse following vaccine administration and the lack of specific recommendations guiding the decision to vaccinate these patients contribute to the low vaccine coverage. More immunogenic vaccine strategy should be evaluated in patients with systemic autoimmune and/or inflammatory diseases to provide better vaccine coverage.